{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:30:18Z","timestamp":1790613018856,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.idc.2025.11.003","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T21:56:48Z","timestamp":1766181408000},"page":"61-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Current Antibiotic Options for the Treatment of Infections with AmpC-Producing Enterobacterales"],"prefix":"10.1016","volume":"40","author":[{"given":"Jinghao Nicholas","family":"Ngiam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Chung Yi","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick N.A.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Chien Boon","family":"Lye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.idc.2025.11.003_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC \u03b2-Lactamases","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin Microbiol Rev"},{"issue":"8","key":"10.1016\/j.idc.2025.11.003_bib2","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/cid\/ciz173","article-title":"A primer on AmpC \u03b2-Lactamases: necessary knowledge for an increasingly multidrug-resistant world","volume":"69","author":"Tamma","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2025.11.003_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlae195","article-title":"AmpC \u03b2-lactamases detected in Southeast Asian Escherichia coli and Klebsiella pneumoniae","volume":"6","author":"Roberts","year":"2024","journal-title":"JAC Antimicrob Resist"},{"issue":"5","key":"10.1016\/j.idc.2025.11.003_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107115","article-title":"Enterobacterales carrying chromosomal AmpC \u03b2-lactamases in Europe (EuESCPM): epidemiology and antimicrobial resistance burden from a cohort of 27 hospitals, 2020-2022","volume":"63","author":"Boattini","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idc.2025.11.003_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2025.11.003_bib6","first-page":"142","article-title":"Antibiotic treatment of infections caused by AmpC-Producing Enterobacterales","volume":"12","author":"Tebano","year":"2024","journal-title":"Pharmacy (Basel)"},{"issue":"12","key":"10.1016\/j.idc.2025.11.003_bib7","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1093\/jac\/dkz362","article-title":"Development of an algorithm to discriminate between plasmid- and chromosomal-mediated AmpC \u03b2-lactamase production in Escherichia coli by elaborate phenotypic and genotypic characterization","volume":"74","author":"Coolen","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idc.2025.11.003_bib8","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3389\/fmicb.2018.00658","article-title":"Carbapenem-resistant E. cloacae in Southwest China: molecular analysis of resistance and risk factors for infections caused by NDM-1-Producers","volume":"9","author":"Jia","year":"2018","journal-title":"Front Microbiol"},{"issue":"3","key":"10.1016\/j.idc.2025.11.003_bib9","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3390\/microorganisms10030611","article-title":"Systematic review of plasmid AmpC type resistances in Escherichia coli and Klebsiella pneumoniae and preliminary proposal of a simplified screening method for ampC","volume":"10","author":"Rodr\u00edguez-Guerrero","year":"2022","journal-title":"Microorganisms"},{"issue":"9","key":"10.1016\/j.idc.2025.11.003_bib10","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.3390\/microorganisms12091777","article-title":"Extended-spectrum Beta-Lactamase- and plasmidic AmpC-Producing Enterobacterales among the faecal samples in the Bulgarian community","volume":"12","author":"Stankova","year":"2024","journal-title":"Microorganisms"},{"issue":"4","key":"10.1016\/j.idc.2025.11.003_bib11","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.22207\/JPAM.16.4.51","article-title":"Molecular characterization of AmpC \u03b2-lactamases in enterobacteriaceae","volume":"16","author":"Bindu","year":"2022","journal-title":"J Pure Appl Microbiol"},{"issue":"3","key":"10.1016\/j.idc.2025.11.003_bib12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.diagmicrobio.2010.02.012","article-title":"High prevalence of extended-spectrum \u03b2-lactamases and plasmid-mediated AmpC \u03b2-lactamases in enterobacteriaceae isolated from long-term care facilities in Korea","volume":"67","author":"Yoo","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2025.11.003_bib13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jgar.2016.06.006","article-title":"Clinical features and molecular epidemiology of plasmid-mediated DHA-type AmpC \u03b2-lactamase-producing Klebsiella pneumoniae blood culture isolates, Hong Kong","volume":"7","author":"Luk","year":"2016","journal-title":"J Glob Antimicrob Resist"},{"issue":"2","key":"10.1016\/j.idc.2025.11.003_bib14","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s12088-011-0214-2","article-title":"Occurrence of plasmid-mediated AmpC \u03b2-Lactamases among Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care Hospital in Bangalore","volume":"52","author":"Sasirekha","year":"2012","journal-title":"Indian J Microbiol"},{"issue":"12","key":"10.1016\/j.idc.2025.11.003_bib15","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.3855\/jidc.13483","article-title":"Prevalence, multidrug-resistance and risk factors for AmpC \u03b2-lactamases producing Escherichia coli from hospitalized patients","volume":"14","author":"Bala","year":"2020","journal-title":"J Infect Dev Ctries"},{"issue":"3","key":"10.1016\/j.idc.2025.11.003_bib16","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1590\/S1517-83822010000300009","article-title":"AmpC beta lactamases among gram negative clinical isolates from a tertiary hospital, South India","volume":"41","author":"Mohamudha","year":"2010","journal-title":"Braz J Microbiol"},{"key":"10.1016\/j.idc.2025.11.003_bib17","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.2147\/IDR.S284751","article-title":"Plasmid-mediated AmpC \u03b2-Lactamase CITM and DHAM genes among gram-negative clinical isolates","volume":"13","author":"Aryal","year":"2020","journal-title":"IDR"},{"issue":"8","key":"10.1016\/j.idc.2025.11.003_bib18","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1128\/JCM.00404-11","article-title":"Practical approach for reliable detection of AmpC beta-lactamase-producing enterobacteriaceae","volume":"49","author":"Polsfuss","year":"2011","journal-title":"J Clin Microbiol"},{"issue":"8","key":"10.1016\/j.idc.2025.11.003_bib19","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1128\/JCM.00091-11","article-title":"Detection of AmpC beta-lactamase in escherichia coli: comparison of three phenotypic confirmation assays and genetic analysis","volume":"49","author":"Peter-Getzlaff","year":"2011","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.idc.2025.11.003_bib20","first-page":"1","article-title":"Detection of AmpC \u03b2 lactamases in gram-negative bacteria","volume":"6","author":"Gupta","year":"2014","journal-title":"J Lab Physicians"},{"issue":"1","key":"10.1016\/j.idc.2025.11.003_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2025.116741","article-title":"Performance of two combination disk methods as confirmation for ESBL and AmpC presence in clinical Enterobacterales isolates","volume":"112","author":"Doornekamp","year":"2025","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"11","key":"10.1016\/j.idc.2025.11.003_bib22","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1128\/JCM.01314-09","article-title":"Use of boronic acid disk tests to detect extended- spectrum beta-lactamases in clinical isolates of KPC carbapenemase-possessing enterobacteriaceae","volume":"47","author":"Tsakris","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.idc.2025.11.003_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/1874285801711010195","article-title":"Co-Occurrence of plasmid-mediated AmpC \u03b2-Lactamase activity among Klebsiella pneumoniae and Escherichia Coli","volume":"11","author":"Zorgani","year":"2017","journal-title":"Open Microbiol J"},{"issue":"6","key":"10.1016\/j.idc.2025.11.003_bib24","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1128\/JCM.40.6.2153-2162.2002","article-title":"Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR","volume":"40","author":"P\u00e9rez-P\u00e9rez","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.idc.2025.11.003_bib25","article-title":"Selective reporting of antibiotic susceptibility testing results: a retrospective evaluation of a nudging strategy to improve antibiotic prescribing for ampC-producing Enterobacterales infections in hospitalized adults","volume":"12","author":"Lim","year":"2025","journal-title":"Ther Adv Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2025.11.003_bib26","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/clinids\/21.5.1107","article-title":"The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I -Lactamase-Producing organisms","volume":"21","author":"Jacobson","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2025.11.003_bib27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0195-6701(88)90084-9","article-title":"Prior antimicrobial therapy and resistance of enterobacter citrobacter and Serratia to third generation cephalosporins","volume":"11","author":"Nicolle","year":"1988","journal-title":"J Hosp Infect"},{"issue":"7","key":"10.1016\/j.idc.2025.11.003_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz248","article-title":"Beta-Lactam\/Beta-Lactamase inhibitor therapy for potential AmpC-Producing organisms: a systematic review and meta-analysis","volume":"6","author":"Cheng","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2025.11.003_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00150-21","article-title":"Class C \u03b2-Lactamases: molecular characteristics","volume":"35","author":"Philippon","year":"2022","journal-title":"Clin Microbiol Rev"},{"issue":"10","key":"10.1016\/j.idc.2025.11.003_bib30","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1128\/AAC.41.10.2177","article-title":"Mechanism of suppression of piperacillin resistance in enterobacteria by tazobactam","volume":"41","author":"Kadima","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2025.11.003_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218589","article-title":"Induction of plasmid-mediated AmpC \u03b2-lactamase DHA-1 by piperacillin\/tazobactam and other \u03b2-lactams in Enterobacteriaceae","volume":"14","author":"Akata","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.idc.2025.11.003_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01038-20","article-title":"Emergence of resistance in Klebsiella aerogenes to piperacillin-tazobactam and ceftriaxone","volume":"65","author":"Custodio","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.idc.2025.11.003_bib33","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1517\/14656566.2016.1154538","article-title":"Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria","volume":"17","author":"D\u2019Angelo","year":"2016","journal-title":"Expet Opin Pharmacother"},{"issue":"11","key":"10.1016\/j.idc.2025.11.003_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00142-24","article-title":"AmpC induction by imipenem in Pseudomonas aeruginosa occurs in the absence of OprD and impacts imipenem\/relebactam susceptibility","volume":"12","author":"Freed","year":"2024","journal-title":"Microbiol Spectr"},{"issue":"11","key":"10.1016\/j.idc.2025.11.003_bib35","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1128\/AAC.01762-09","article-title":"Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC \u03b2-Lactamases","volume":"54","author":"Mammeri","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2025.11.003_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00079-17","article-title":"Treatment of infections caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and carbapenemase-producing enterobacteriaceae","volume":"31","author":"Rodr\u00edguez-Ba\u00f1o","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.idc.2025.11.003_bib37","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1111\/j.1469-0691.1999.tb00721.x","article-title":"In vitro selective concentrations of cefepime and ceftazidime for AmpC \u03b2-lactamase hyperproducer Enterobacter cloacae variants","volume":"5","author":"Negri","year":"1999","journal-title":"Clin Microbiol Infection"},{"issue":"6","key":"10.1016\/j.idc.2025.11.003_bib38","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/cid\/cit395","article-title":"The use of cefepime for treating AmpC \u03b2-Lactamase\u2013Producing enterobacteriaceae","volume":"57","author":"Tamma","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2025.11.003_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad175","article-title":"The frequency of extended-spectrum \u03b2-Lactamase genes harbored by Enterobacterales isolates at high risk for clinically significant chromosomal ampC expression","volume":"10","author":"Hareza","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2025.11.003_bib40","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1128\/JCM.43.10.5058-5064.2005","article-title":"SHV-type extended-spectrum beta-lactamase production is associated with reduced cefepime susceptibility in Enterobacter cloacae","volume":"43","author":"Szab\u00f3","year":"2005","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.idc.2025.11.003_bib41","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/crj.12674","article-title":"Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association","volume":"12","author":"Cao","year":"2018","journal-title":"Clinical Respiratory J"},{"issue":"2","key":"10.1016\/j.idc.2025.11.003_bib42","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jac\/dkv346","article-title":"Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter , Citrobacter or Serratia species: a systematic review with meta-analysis","volume":"71","author":"Harris","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.idc.2025.11.003_bib43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/0003-4819-115-8-585","article-title":"Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy","volume":"115","author":"Chow","year":"1991","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.idc.2025.11.003_bib44","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1128\/AAC.45.9.2628-2630.2001","article-title":"Risk factors for emergence of resistance to broad-spectrum cephalosporins among enterobacter spp","volume":"45","author":"Kaye","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2025.11.003_bib45","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1128\/AAC.01083-07","article-title":"Emergence of antibiotic resistance during therapy for infections caused by enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use","volume":"52","author":"Choi","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idc.2025.11.003_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2025.05.006","article-title":"Which trial do we need? Ceftriaxone vs. meropenem for infections due to AmpC-producing enterobacterales","author":"Aparicio-Minguij\u00f3n","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.idc.2025.11.003_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2024.116557","article-title":"Ceftriaxone versus cefepime or carbapenems for definitive treatment of low-risk AmpC-Harboring Enterobacterales bloodstream infections in hospitalized adults: a retrospective cohort study","volume":"111","author":"Mulbah","year":"2025","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2025.11.003_bib48","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00276-17","article-title":"Piperacillin-tazobactam versus other antibacterial agents for treatment of bloodstream infections due to AmpC \u03b2-Lactamase-Producing enterobacteriaceae","volume":"61","author":"Cheng","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.idc.2025.11.003_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106809","article-title":"Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC \u03b2-lactamase-producing enterobacterales: a multi-centre retrospective propensity-weighted study","volume":"62","author":"Maillard","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1016\/j.idc.2025.11.003_bib50","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jiac.2018.03.011","article-title":"Risk factors for death from Stenotrophomonas maltophilia bacteremia","volume":"24","author":"Osawa","year":"2018","journal-title":"J Infect Chemother"},{"issue":"4","key":"10.1016\/j.idc.2025.11.003_bib51","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/jac\/dkad037","article-title":"Piperacillin\/Tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients","volume":"78","author":"Lu","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.idc.2025.11.003_bib52","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s15010-024-02447-y","article-title":"Piperacillin\/Tazobactam vs. cefepime or carbapenems for the treatment of bloodstream infections due to bacteria producing chromosomal AmpC beta-lactamase: a systematic review and meta-analysis","volume":"53","author":"Onorato","year":"2025","journal-title":"Infection"},{"issue":"8","key":"10.1016\/j.idc.2025.11.003_bib53","doi-asserted-by":"crossref","first-page":"ofab387","DOI":"10.1093\/ofid\/ofab387","volume":"8","author":"Stewart","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.idc.2025.11.003_bib54","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf413","article-title":"Cefepime versus carbapenem therapy for the treatment of invasive infections with inducible chromosomal AmpC-Producing enterobacterales\u2014A systematic review and meta-analysis","author":"Cheo","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2025.11.003_bib55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10096-023-04715-5","article-title":"Cefepime versus carbapenems for treatment of AmpC beta-lactamase-producing Enterobacterales bloodstream infections","volume":"43","author":"Herrmann","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2025.11.003_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.105860","article-title":"Outcomes of treating AmpC-producing Enterobacterales bacteraemia with carbapenems vs. non-carbapenems","volume":"55","author":"Tan","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"10.1016\/j.idc.2025.11.003_bib57","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1128\/AAC.01477-15","article-title":"Cefepime therapy for monomicrobial Enterobacter cloacae bacteremia: unfavorable outcomes in patients infected by cefepime-susceptible dose-dependent isolates","volume":"59","author":"Lee","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.idc.2025.11.003_bib58","article-title":"High-dose cefepime vs carbapenems for bacteremia caused by Enterobacterales with moderate to high risk of clinically significant AmpC \u03b2-lactamase production","volume":"10","author":"Kunz","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.11.003_bib59","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13054-017-1856-1","article-title":"Cefepime-induced neurotoxicity: a systematic review","volume":"21","author":"Payne","year":"2017","journal-title":"Crit Care"},{"issue":"4","key":"10.1016\/j.idc.2025.11.003_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107288","article-title":"Risk of Clostridioides difficile infection following different antibiotics: insights from multi-source medical data","volume":"64","author":"Liu","year":"2024","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"10.1016\/j.idc.2025.11.003_bib61","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00845-19","article-title":"Antecedent carbapenem exposure as a risk factor for non-carbapenemase-producing carbapenem-resistant enterobacteriaceae and carbapenemase-producing enterobacteriaceae","volume":"63","author":"Marimuthu","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.idc.2025.11.003_bib62","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3390\/antibiotics13080709","article-title":"Clinical outcomes of patients with ampc-beta-lactamase-producing Enterobacterales bacteremia treated with carbapenems versus non-carbapenem regimens: a single-center study","volume":"13","author":"Shalabi","year":"2024","journal-title":"Antibiotics (Basel)"},{"issue":"6","key":"10.1016\/j.idc.2025.11.003_bib63","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40265-017-0725-1","article-title":"Novel beta-lactamase inhibitors: unlocking their potential in therapy","volume":"77","author":"Wong","year":"2017","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.idc.2025.11.003_bib64","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1093\/jac\/dky317","article-title":"Stability and low induction propensity of cefiderocol against chromosomal AmpC \u03b2-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae","volume":"73","author":"Ito","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.idc.2025.11.003_bib65","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00675-18","article-title":"In vitro activity of ceftolozane-tazobactam against Enterobacter cloacae complex clinical isolates with different \u03b2-Lactam resistance phenotypes","volume":"62","author":"Robin","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552025000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552025000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:42:16Z","timestamp":1773780136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552025000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0891552025000972"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2025.11.003","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Antibiotic Options for the Treatment of Infections with AmpC-Producing Enterobacterales","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2025.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}